Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E59.03 EPS (ttm)0.49 Insider Own0.90% Shs Outstand301.94M Perf Week-1.49%
Market Cap8.79B Forward P/E37.45 EPS next Y0.78 Insider Trans-25.15% Shs Float285.66M Perf Month-4.28%
Income150.90M PEG1.28 EPS next Q0.12 Inst Own82.10% Short Float5.65% Perf Quarter13.45%
Sales410.00M P/S21.43 EPS this Y63.70% Inst Trans-0.94% Short Ratio6.22 Perf Half Y7.78%
Book/sh0.81 P/B35.93 EPS next Y57.61% ROA26.10% Target Price34.00 Perf Year28.65%
Cash/sh1.22 P/C23.93 EPS next 5Y46.00% ROE101.20% 52W Range18.03 - 32.50 Perf YTD-4.28%
Dividend- P/FCF46.42 EPS past 5Y-19.90% ROI-15.10% 52W High-10.46% Beta1.82
Dividend %- Quick Ratio4.30 Sales past 5Y-7.90% Gross Margin96.90% 52W Low61.40% ATR1.23
Employees287 Current Ratio4.30 Sales Q/Q145.20% Oper. Margin39.30% RSI (14)49.94 Volatility2.86% 4.24%
OptionableYes Debt/Eq0.00 EPS Q/Q690.80% Profit Margin36.80% Rel Volume0.64 Prev Close28.99
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 AMC Payout0.00% Avg Volume2.60M Price29.10
Recom2.30 SMA20-1.60% SMA50-0.36% SMA20011.68% Volume1,656,012 Change0.38%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Feb-22-18 08:20AM  Todays Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis ACCESSWIRE
Feb-21-18 08:52AM  Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again? Zacks
Feb-20-18 08:27AM  Novartis Psoriasis Drug Cosentyx Positive in SCALP Study Zacks
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
08:43AM  Celgene Reports Positive Data on Dermatology Drug Otezla Zacks
Feb-16-18 10:16AM  Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat Zacks
08:53AM  Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion Zacks
06:08AM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb Motley Fool
Feb-15-18 03:01PM  Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates Zacks
08:02AM  Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva Zacks
Feb-14-18 05:55PM  Roche's Rituxan Gets Priority Review for Label Expansion Zacks
05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
04:05PM  Exelixis to Present at the RBC Capital Markets Global Healthcare Conference on February 21, 2018 Business Wire
01:43PM  Exelixis Reports Positive Data From Thyroid Carcinoma Trial Zacks
11:14AM  Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling Zacks
Feb-13-18 04:05PM  Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma Business Wire
10:35AM  Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval Zacks
08:30AM  Todays Research Reports on Trending Tickers: Exelixis and 22nd Century Group ACCESSWIRE
08:16AM  Intercept Starts OCA Trial for NASH Patients With Cirrhosis Zacks
Feb-09-18 11:35AM  FDA Okays J&J's Prostate Cancer Drug in First-Line Setting Zacks
Feb-08-18 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2017 Financial Results on Monday, February 26, 2018 Business Wire -7.13%
11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-07-18 08:14AM  Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural Zacks
08:00AM  Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors Business Wire
Feb-06-18 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 14 Business Wire
01:09PM  5 Biotech Stocks Set to Trump Estimates This Earnings Season Zacks
10:19AM  Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study Zacks
10:10AM  Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study Zacks
10:00AM  Pfizer Files for Xtandi in Early Stage Prostate Cancer Zacks
09:23AM  5 of the Best Efficient Stocks for Your Portfolio Zacks
Feb-05-18 07:10PM  Cramer's lightning round: Tableau Software is exactly the... CNBC Videos -5.82%
08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
Feb-03-18 09:20AM  Top 5 Biotech Stocks for 2018 Investopedia
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
09:30AM  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review Zacks
08:16AM  Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings? Zacks
Feb-01-18 09:50AM  Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa Zacks
07:50AM  Report: Developing Opportunities within Omega Flex, Sun, First Citizens BancShares, Zynga, Infinera, and Exelixis Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-31-18 09:44AM  Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label Zacks
09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 11:14AM  Theravance's NDA for COPD Candidate Gets FDA Acceptance Zacks
09:50AM  Roche Gets Breakthrough Therapy Designation For ASD Drug Zacks
Jan-29-18 04:24PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
10:22AM  Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion Zacks
09:51AM  Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat Zacks
Jan-25-18 10:30AM  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks
10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
07:02AM  The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Bio-Techne, Exelixis, Paratek and Bioverativ Zacks
Jan-23-18 04:37PM  Novartis Announces Positive Results on Migraine Candidate Zacks
10:45AM  Anthera's Sollpura Strong on Positive Futility in Phase III Zacks
09:44AM  Seattle Genetics' Adcetris Gets EU Nod for Label Expansion Zacks
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
09:26AM  BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall Zacks
08:57AM  Fancy Biotech Stocks on Buyout Buzz? 5 Top Picks Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks +5.14%
Jan-20-18 10:55AM  Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-19-18 10:59AM  Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year Zacks
10:23AM  Cancer Space Update: Label Expansions, Data Readouts in Focus Zacks
08:46AM  BeiGene (BGNE) Surges: Stock Moves 12.6% Higher Zacks
Jan-18-18 10:04AM  BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa Zacks
Jan-17-18 04:19PM  Why This Biotech Stock Is Diving Despite In-Line Liver Cancer Results Investor's Business Daily -7.28%
10:48AM  Merck Strong on Confirmatory Phase III Lung Cancer Study Zacks
09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
08:06AM  Exelixis, Ipsen Report Positive Results on Lead Cancer Drug Zacks
Jan-16-18 05:33PM  Exelixis, Ipsen report positive cancer-study results MarketWatch
05:01PM  Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma Business Wire
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
10:12AM  Endo (ENDP) Loses 35% in a Year: Can It Turn Around in 2018? Zacks
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
08:35AM  Novartis (NVS) Announces Acceptance of Humira BLA by the FDA Zacks
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
Jan-15-18 08:24AM  Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion Zacks
07:37AM  Prothena (PRTA) Tumbles 18% in a Year: What Lies Ahead? Zacks
06:53AM  Roche MS Drug Ocrevus Gets Marketing Authorization in Europe Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
09:05AM  Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod Zacks
08:04AM  Endo (ENDP) Gets Subpoena From Florida for Opioid Misuse Zacks
Jan-11-18 10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
12:02AM  How Do Analysts See Exelixis Inc (NASDAQ:EXEL) Performing Over The Next Few Years? Simply Wall St.
Jan-10-18 10:33AM  4 Reasons Exelixis, Inc. More Than Doubled in 2017 Motley Fool
09:00AM  Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home Zacks
09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 05:04PM  Emergent Down on '18 View, Posts Preliminary '17 Results Zacks
04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
08:48AM  Agenus Inc., (AGEN) Jumps: Stock Rises 11.4% Zacks
08:00AM  Exelixis to Co-Host Financial Community Briefing to Discuss Data Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Business Wire
Jan-08-18 03:42PM  Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma Zacks -7.34%
08:54AM  Alnylam, Sanofi Announce Restructuring Deal for RNAi Products Zacks
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
08:00AM  Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies Business Wire
Jan-05-18 04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
01:43PM  Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial Zacks
09:47AM  Emergent Starts Phase II Study on Anti-influenza Candidate Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garber Alan MDirectorJan 09Option Exercise7.9711,50091,65572,829Jan 10 07:27 PM
Garber Alan MDirectorJan 09Sale30.0011,500345,00061,329Jan 10 07:27 PM
Garber Alan MDirectorJan 08Option Exercise7.973,50027,89564,829Jan 10 07:27 PM
Garber Alan MDirectorJan 08Sale31.293,500109,51561,329Jan 10 07:27 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-8.28 Insider Own0.50% Shs Outstand49.40M Perf Week10.70%
Market Cap2.96B Forward P/E- EPS next Y-3.60 Insider Trans-9.85% Shs Float47.46M Perf Month-6.58%
Income-365.20M PEG- EPS next Q-1.30 Inst Own- Short Float15.67% Perf Quarter-6.26%
Sales38.50M P/S76.83 EPS this Y7.40% Inst Trans1.90% Short Ratio6.01 Perf Half Y-16.95%
Book/sh6.12 P/B9.78 EPS next Y53.10% ROA-57.10% Target Price93.00 Perf Year-2.14%
Cash/sh12.71 P/C4.71 EPS next 5Y- ROE-179.60% 52W Range45.42 - 99.45 Perf YTD-11.94%
Dividend- P/FCF- EPS past 5Y-29.60% ROI- 52W High-39.79% Beta1.16
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin81.90% 52W Low31.84% ATR3.13
Employees278 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)57.42 Volatility4.13% 5.15%
OptionableYes Debt/Eq0.94 EPS Q/Q27.30% Profit Margin- Rel Volume2.90 Prev Close54.93
ShortableYes LT Debt/Eq0.94 EarningsFeb 26 AMC Payout- Avg Volume1.24M Price59.88
Recom2.10 SMA206.48% SMA50-0.66% SMA200-14.16% Volume3,583,413 Change9.01%
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Jul-07-17Initiated Gabelli & Co Buy $125
Jun-23-17Initiated Oppenheimer Perform
Jun-20-17Upgrade Janney Neutral → Buy
Jun-19-17Upgrade Chardan Capital Markets Sell → Neutral $36 → $50
Jun-16-17Resumed Credit Suisse Outperform
Jun-13-17Initiated Leerink Partners Outperform $85
May-17-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Downgrade Chardan Capital Markets Neutral → Sell $36
Jan-27-17Initiated BofA/Merrill Buy $74
Jan-26-17Upgrade Piper Jaffray Neutral → Overweight
Jan-23-17Reiterated Stifel Buy $52 → $86
Jan-13-17Initiated Morgan Stanley Overweight
Dec-21-16Reiterated WallachBeth Hold $22 → $49
Dec-20-16Upgrade Chardan Capital Markets Sell → Neutral $15 → $36
Oct-25-16Initiated Chardan Capital Markets Sell $15
Feb-22-18 08:43AM  Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season? Zacks +9.01%
Feb-21-18 05:10PM  Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication Business Wire
Feb-12-18 04:05PM  Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26 Business Wire
Jan-22-18 09:42AM  AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan Zacks +6.89%
Jan-12-18 08:20AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation ACCESSWIRE
Jan-05-18 04:39PM  Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 Investor's Business Daily
Jan-04-18 08:00AM  Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Dec-28-17 09:10AM  Clovis Up More Than 50% in 2017: What's Driving the Stock? Zacks
Dec-19-17 08:00AM  Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018 Business Wire
Dec-15-17 03:00AM  Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold Investor's Business Daily
Dec-13-17 12:41PM  Value Biotech ETFs to Buy Now Zacks
Dec-06-17 03:09PM  Clovis' sNDA for Rubraca Gets Priority Review in the U.S. Zacks
02:08PM  Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down Investor's Business Daily
09:30AM  Clovis Up On Priority Review Status for Ovarian Cancer Therapy -- Biotech Movers TheStreet.com
09:30AM  Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover TheStreet.com
07:46AM  Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data Zacks
Dec-05-17 08:25PM  Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug American City Business Journals
04:05PM  Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application Business Wire
Nov-28-17 11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-24-17 11:24AM  3 Companies Competing to Gain Lead in Ovarian Cancer Market Zacks
Nov-21-17 10:25AM  TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU Zacks
08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-20-17 08:20AM  Todays Research Reports on Trending Tickers: Ekso Bionics and Clovis Oncology ACCESSWIRE
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Nov-14-17 02:55PM  CORRECTING and REPLACING Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-17 06:45PM  Edited Transcript of CLVS earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
07:50AM  Recent Analysis Shows Pure Storage, Catalent, Boyd Gaming, Halozyme Therapeutics, Clovis Oncology, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-08-17 06:40PM  Clovis Oncology to Present at the Stifel 2017 Healthcare Conference Business Wire
01:45PM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : November 8, 2017 Capital Cube
07:40AM  Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab ACCESSWIRE
Nov-02-17 11:49AM  Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss Zacks
Nov-01-17 06:26PM  Clovis reports 3Q loss Associated Press
05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:05PM  Clovis Oncology Announces Third Quarter 2017 Operating Results Business Wire
12:00PM  Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-17 11:13AM  What's in the Cards for Immune Design (IMDZ) in Q3 Earnings? Zacks
Oct-26-17 12:16PM  Allergan (AGN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-17 10:23AM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : October 25, 2017 Capital Cube
07:00AM  Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors CNW Group
Oct-24-17 08:14AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : October 24, 2017 Capital Cube
Oct-23-17 08:00AM  Clovis Oncology to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 1 Business Wire
Oct-17-17 08:39AM  Gilead Sciences on the Street: Analyst Recommendations in October Market Realist
08:05AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-16-17 08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-11-17 08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
Oct-10-17 10:50AM  Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca Zacks
Oct-09-17 04:05PM  Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer Business Wire
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-05-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Oct-04-17 11:40AM  Cancer-Cure Makers Make Great Takeover Stocks Forbes
Oct-03-17 04:22PM  These Biotechs Slump As Report Suggests Discounting Their Drugs Investor's Business Daily
Sep-28-17 03:00AM  Clovis Oncology Scores Relative Strength Rating Upgrade Investor's Business Daily
Sep-26-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Sep-25-17 08:10AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017 Capital Cube
Sep-19-17 08:51AM  Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology ACCESSWIRE
Sep-18-17 04:02PM  Clovis Up 10% On Double Normal Volume Forbes +10.48%
03:44PM  So Much PARP Inhibitor Deal Hype, So Little Payoff Bloomberg
Sep-13-17 06:00AM  Clovis Oncologys Rucaparib ARIEL3 Study Data Published in The Lancet Business Wire
Sep-12-17 03:08PM  Should You Keep Your Portfolio Healthy with Biotech ETFs? Zacks
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
06:30AM  A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It Forbes
Sep-08-17 10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com -7.12%
Sep-07-17 06:05PM  Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017 Business Wire
04:18PM  Why Clovis Oncology Fell 7.1% in August Motley Fool
05:12AM  Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? Zacks
Sep-06-17 08:01AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Sep-02-17 10:20AM  Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition TheStreet.com
Aug-30-17 02:58PM  After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next? Forbes
08:00AM  Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress Business Wire
Aug-23-17 04:59PM  Here's Why Clovis Stock Is Up Almost 60% So Far in 2017 Zacks
08:04AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-18-17 06:33PM  Tesaro: Losing Its Edge? Barrons.com
04:27PM  Ovarian Cancer Market Still Up For Grabs Barrons.com
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
Aug-16-17 08:16PM  Clovis Oncology, Inc. Value Analysis (NASDAQ:CLVS) : August 17, 2017 Capital Cube
08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-15-17 09:20AM  Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses Zacks
Aug-14-17 08:01AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-13-17 08:10AM  Edited Transcript of CLVS earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-11-17 08:03AM  See what the IHS Markit Score report has to say about Clovis Oncology Inc. Markit
Aug-10-17 08:04AM  IHS Markit Score Update: Drop in demand for ETFs holding Clovis Oncology Inc is a negative sign for its shares Markit
Aug-09-17 09:02AM  Biotech: Why Clovis And Tesaro Look Well Positioned Barrons.com -6.11%
Aug-08-17 02:36PM  A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision Benzinga
Aug-04-17 09:52AM  Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4, 2017 Capital Cube
Aug-03-17 11:47AM  One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce? TheStreet.com -5.12%
09:57AM  Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses Zacks
Aug-02-17 10:57PM  Clovis reports 2Q loss Associated Press
04:05PM  Clovis Oncology Announces Second Quarter 2017 Operating Results Business Wire
10:50AM  Investor Network: Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-17 04:51PM  Why Clovis Oncology Tumbled 13.5% Today Motley Fool -13.48%
04:30PM  Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today Motley Fool
04:11PM  Why Clovis, Regeneron Are Leading A Biotech Deluge Today Investor's Business Daily
01:45PM  Clovis Sell-Off May Be Overdone TheStreet.com
12:10PM  Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Clovis Oncology Inc. and Intercept Pharmaceuticals Inc. ACCESSWIRE
07:10AM  Bristol-Myers and Clovis will partner for cancer combination trials MarketWatch
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. The company is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications. It distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. The company has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and Celgene Corporation; and collaboration and license agreement with Les Laboratoires Servier; and a clinical collaboration with Bristol-Myers Squibb Company to evaluate combination of Opdivo (Nivolumab) and Rubraca (rucaparib) in Phase 2 and pivotal Phase 3 clinical trials in multiple tumor types. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksFeb 15Sale54.093,000162,270180,571Feb 16 07:54 PM
IVERS-READ GILLIAN CSee RemarksJan 16Sale59.163,000177,480183,571Jan 17 04:45 PM
SPICKSCHEN THORLEFDirectorJan 08Sale64.974,500292,36521,118Jan 09 04:45 PM
IVERS-READ GILLIAN CSee RemarksDec 15Sale64.163,000192,480182,583Dec 18 04:45 PM
SPICKSCHEN THORLEFDirectorDec 08Sale60.004,500270,00025,618Dec 08 09:32 PM
IVERS-READ GILLIAN CSee RemarksNov 15Sale63.703,000191,100185,583Nov 16 04:45 PM
IVERS-READ GILLIAN CSee RemarksOct 16Sale84.543,000253,620188,583Oct 17 08:13 PM
IVERS-READ GILLIAN CSee RemarksSep 15Sale69.503,000208,500191,583Sep 18 04:35 PM
IVERS-READ GILLIAN CSee RemarksAug 15Sale70.053,000210,150194,583Aug 15 04:53 PM
BLAIR JAMES CDirectorAug 04Sale78.6118,4501,450,35517,056Aug 08 04:03 PM
IVERS-READ GILLIAN CSee RemarksJul 17Sale91.563,000274,680197,583Jul 17 06:07 PM
IVERS-READ GILLIAN CSee RemarksJun 15Sale61.823,000185,460200,583Jun 15 05:42 PM
IVERS-READ GILLIAN CSee RemarksMay 15Sale47.393,000142,170203,583May 15 06:24 PM
IVERS-READ GILLIAN CSee RemarksApr 17Sale56.023,000168,060206,583Apr 17 06:04 PM
IVERS-READ GILLIAN CSee RemarksMar 15Sale66.993,000200,970209,583Mar 15 05:15 PM
HCI HCI Group, Inc. daily Stock Chart
HCI [NYSE]
HCI Group, Inc.
Index- P/E- EPS (ttm)-1.65 Insider Own15.00% Shs Outstand9.68M Perf Week0.42%
Market Cap343.35M Forward P/E9.10 EPS next Y3.90 Insider Trans1.01% Shs Float7.69M Perf Month0.91%
Income-13.50M PEG- EPS next Q0.81 Inst Own75.60% Short Float12.45% Perf Quarter16.95%
Sales257.10M P/S1.34 EPS this Y-50.50% Inst Trans-9.72% Short Ratio6.28 Perf Half Y-11.83%
Book/sh22.66 P/B1.57 EPS next Y363.50% ROA-0.90% Target Price43.25 Perf Year-25.50%
Cash/sh30.21 P/C1.17 EPS next 5Y25.00% ROE-3.10% 52W Range27.11 - 50.93 Perf YTD18.63%
Dividend1.40 P/FCF5.82 EPS past 5Y16.90% ROI10.50% 52W High-30.36% Beta2.16
Dividend %3.95% Quick Ratio- Sales past 5Y23.20% Gross Margin- 52W Low30.84% ATR1.08
Employees331 Current Ratio- Sales Q/Q-31.80% Oper. Margin1.00% RSI (14)57.04 Volatility3.06% 3.03%
OptionableYes Debt/Eq1.22 EPS Q/Q-503.00% Profit Margin-2.70% Rel Volume0.28 Prev Close35.73
ShortableYes LT Debt/Eq1.22 EarningsMar 06 AMC Payout- Avg Volume152.32K Price35.47
Recom2.20 SMA201.01% SMA507.20% SMA200-7.52% Volume42,404 Change-0.73%
Sep-11-17Upgrade Sidoti Neutral → Buy
Apr-07-17Initiated SunTrust Buy $52
Dec-28-15Initiated Piper Jaffray Overweight
Oct-20-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $47
Mar-17-15Downgrade Gilford Securities Buy → Neutral $50
Oct-03-14Upgrade Gilford Securities Neutral → Buy $46.50 → $52
Oct-24-13Downgrade Gilford Securities Buy → Neutral $44.50 → $45.60
Aug-30-13Upgrade Gilford Securities Neutral → Buy $37.50 → $44.50
Aug-02-13Reiterated Gilford Securities Neutral $36 → $37.50
May-28-13Downgrade Taglich Brothers Buy → Speculative Buy $22 → $38
May-08-13Downgrade Gilford Securities Buy → Neutral
Apr-01-13Reiterated Taglich Brothers Buy $27.35 → $31.95
Mar-06-13Reiterated Gilford Securities Buy $26 → $30
Feb-12-18 08:00AM  HCI Group Sets Fourth Quarter and Full Year 2017 Earnings Call for Tuesday, March 6, 2018 at 4:45 p.m. ET GlobeNewswire
Jan-24-18 08:30AM  Market Trends Toward New Normal in HCI Group, Mitek, Duluth, Gentherm, Masonite International, and AmeriGas Partners Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-22-18 08:00AM  HCI Group Declares Q1 2018 Regular Quarterly Cash Dividend GlobeNewswire
Jan-16-18 08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in California GlobeNewswire
Dec-28-17 08:20AM  Year in Review: First Coast's tech successes in 2017 American City Business Journals
Dec-15-17 01:29PM  ETFs with exposure to HCI Group, Inc. : December 15, 2017 Capital Cube
Dec-12-17 08:00AM  HCI Group Appoints Karin Coleman to Executive Vice President GlobeNewswire
Dec-06-17 08:00AM  HCI Group Board Authorizes $20 Million Stock Repurchase Program for 2018 GlobeNewswire
Dec-05-17 12:56PM  ETFs with exposure to HCI Group, Inc. : December 5, 2017 Capital Cube
Dec-01-17 08:45AM  HCI Group, Inc. :HCI-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017 Capital Cube
Nov-30-17 08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in Ohio GlobeNewswire
Nov-17-17 10:17AM  HCI Group, Inc. : HCI-US: Dividend Analysis : November 17th, 2017 (record date) : By the numbers : November 17, 2017 Capital Cube
Nov-07-17 07:34PM  Edited Transcript of HCI earnings conference call or presentation 2-Nov-17 8:45pm GMT Thomson Reuters StreetEvents
Nov-06-17 11:45AM  ETFs with exposure to HCI Group, Inc. : November 6, 2017 Capital Cube
05:38AM  HCI Group reports 3Q loss Associated Press
Nov-02-17 04:15PM  HCI Group Reports Third Quarter and Nine-Month 2017 Results GlobeNewswire
12:20PM  HCI Group, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 08:27AM  HCI Group, Inc. breached its 50 day moving average in a Bearish Manner : HCI-US : November 1, 2017 Capital Cube
Oct-27-17 08:00AM  HCI Group Real Estate Division Acquires New Office Building GlobeNewswire
Oct-24-17 08:00AM  HCI Group Declares Q4 2017 Regular Quarterly Cash Dividend GlobeNewswire
Oct-20-17 09:17AM  New Strong Sell Stocks for October 20th Zacks
Oct-17-17 10:13AM  HCI Group, Inc. Value Analysis (NYSE:HCI) : October 17, 2017 Capital Cube
Oct-16-17 08:09AM  HCI Group, Inc. breached its 50 day moving average in a Bullish Manner : HCI-US : October 16, 2017 Capital Cube
Oct-09-17 08:00AM  HCI Group Sets Third Quarter 2017 Earnings Call for Thursday, November 2, 2017 at 4:45 p.m. ET GlobeNewswire
Oct-06-17 05:06PM  State Auto Financial (STFC) Projects Q3 Cat Loss Estimates Zacks
08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in North Carolina GlobeNewswire
Sep-27-17 09:29AM  United Insurance (UIHC) Keeps a Count of Q3 Catastrophe Loss Zacks
Sep-25-17 04:00PM  Allstate Estimates Catastrophe Loss from Hurricane Harvey Zacks
Sep-21-17 08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in New Jersey GlobeNewswire
Sep-19-17 10:33AM  HCI Group (HCI) Calculates Possible Irma Catastrophe Loss Zacks
08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in Texas GlobeNewswire
Sep-18-17 05:56PM  ETFs with exposure to HCI Group, Inc. : September 18, 2017 Capital Cube
08:00AM  HCI Group Insurance Subsidiaries Issue Loss Estimates from Hurricane Irma GlobeNewswire
Sep-15-17 03:16PM  HCI Group, Inc. : HCI-US: Dividend Analysis : August 18th, 2017 (record date) : By the numbers : September 15, 2017 Capital Cube
11:51AM  HCI Group, Inc. :HCI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 15, 2017 Capital Cube
Sep-12-17 05:00PM  Universal Insurance and other big Florida insurers see a quick rebound in stock prices American City Business Journals
Sep-11-17 08:05AM  How Tampa Bay and Florida insurers are making it through the storm American City Business Journals +17.48%
Sep-08-17 01:40PM  Hurricane Irma causes Florida insurance stocks to plunge American City Business Journals
10:22AM  The Zacks Analyst Blog Highlights: HCI Group, Lumber Liquidators, Tempur Sealy International and Home Depot Zacks
Sep-07-17 04:30PM  Hurricane Irma: These Insurance Stocks Have the Most Exposure to Florida Zacks -8.46%
08:48AM  HCI Group (HCI) in Focus: Stock Moves 5.8% Higher Zacks
Sep-06-17 11:08AM  ETFs to Watch in Harvey Aftermath & New Hurricane Irma Zacks +5.79%
Sep-05-17 03:25PM  Irma batters Tampa Bay insurance stocks American City Business Journals -20.01%
Aug-25-17 08:15AM  HCI Group to Participate at the 6th Annual Liolios Gateway Conference and the 2017 KBW Insurance Conference in September 2017 GlobeNewswire
08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in South Carolina GlobeNewswire
Aug-23-17 08:34AM  Liolios Releases Presenting Company Roster for its 6th Annual Gateway Conference on September 6-7 in San Francisco GlobeNewswire
Aug-17-17 08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in Maryland GlobeNewswire
Aug-12-17 01:50AM  Edited Transcript of HCI earnings conference call or presentation 2-Aug-17 8:45pm GMT Thomson Reuters StreetEvents
Aug-04-17 03:22AM  HCI Group posts 2Q profit Associated Press
Aug-02-17 04:15PM  HCI Group Reports Second Quarter and Six-Month 2017 Results GlobeNewswire
Aug-01-17 04:10PM  Investor Network Invites You to the HCI Group Second Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, August 2, 2017 ACCESSWIRE
Jul-31-17 06:25PM  HCI Group, Inc. Value Analysis (NYSE:HCI) : July 31, 2017 Capital Cube
Jul-17-17 09:48AM  HCI Group, Inc. breached its 50 day moving average in a Bearish Manner : HCI-US : July 17, 2017 Capital Cube
Jul-14-17 08:05AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in Pennsylvania GlobeNewswire
08:00AM  HCI Group Subsidiary Homeowners Choice Approved to Write Flood Insurance in Arkansas GlobeNewswire
Jul-10-17 08:00AM  HCI Group Declares Q3 2017 Regular Quarterly Cash Dividend GlobeNewswire
Jun-22-17 08:00AM  HCI Group Insurance Subsidiaries Expand Flood Insurance into Nine Additional States GlobeNewswire
Jun-13-17 04:15PM  HCI Group to Participate at the JMP Financial Services and Real Estate Conference on Thursday, June 22, 2017 GlobeNewswire
Jun-12-17 02:07PM  ETFs with exposure to HCI Group, Inc. : June 12, 2017 Capital Cube
Jun-09-17 09:46AM  HCI Group, Inc. :HCI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
08:10AM  HCI Group, Inc. breached its 50 day moving average in a Bullish Manner : HCI-US : June 9, 2017 Capital Cube
Jun-01-17 08:30AM  HCI Group Insurance Subsidiary, Homeowners Choice, Improves Coverage and Reduces Risk GlobeNewswire
May-19-17 12:11PM  HCI Group, Inc. : HCI-US: Dividend Analysis : May 19th, 2017 (record date) : By the numbers : May 19, 2017 Capital Cube
May-10-17 07:05PM  Edited Transcript of HCI earnings conference call or presentation 4-May-17 8:45pm GMT Thomson Reuters StreetEvents
May-05-17 05:03AM  HCI Group posts 1Q profit Associated Press
May-04-17 04:15PM  HCI Group Reports First Quarter 2017 Results GlobeNewswire
May-03-17 04:10PM  Investor Network Invites You to the HCI Group First Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, May 4, 2017 Accesswire
Apr-26-17 08:22AM  HCI Group, Inc. breached its 50 day moving average in a Bullish Manner : HCI-US : April 26, 2017 Capital Cube
Apr-24-17 03:10PM  Heres what happened when HCI Groups biggest shareholder bought more stock American City Business Journals
08:00AM  HCI Group Terminates Shareholder Rights Plan GlobeNewswire
Apr-19-17 08:00AM  HCI Group Declares Q2 2017 Regular Quarterly Cash Dividend GlobeNewswire
Apr-17-17 08:00AM  HCI Group Sets First Quarter 2017 Earnings Call for Thursday, May 4, 2017 at 4:45 p.m. ET GlobeNewswire
Apr-12-17 08:05AM  HCI Group, Inc. breached its 50 day moving average in a Bullish Manner : HCI-US : April 12, 2017 Capital Cube
Apr-05-17 04:05PM  HCI Group Completes Redemption of 8% Series A Senior Notes Due 2020 GlobeNewswire
Mar-31-17 08:09AM  HCI Group, Inc. breached its 50 day moving average in a Bullish Manner : HCI-US : March 31, 2017 Capital Cube
Mar-27-17 10:59AM  HCI Group, Inc. : HCI-US: Dividend Analysis : February 17th, 2017 (record date) : By the numbers : March 27, 2017 Capital Cube
Mar-14-17 04:01PM  HCI Group to Redeem 8% Senior Notes Due 2020 GlobeNewswire
Mar-13-17 08:00AM  HCI Group Sets Annual Shareholders' Meeting and Record Date GlobeNewswire
Mar-03-17 04:21PM  HCI GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
Mar-01-17 09:24AM  Torchmark (TMK) Rewards Shareholders with 7% Dividend Hike
Feb-28-17 07:04PM  HCI GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an
01:04PM  HCI GROUP, INC. Financials
09:15AM  HCI Group Announces Pricing of $125 Million Offering of Convertible Senior Notes Due 2037 GlobeNewswire
06:00AM  HCI Group Announces Proposed $115 Million Offering of Convertible Senior Notes Due 2037 GlobeNewswire
Feb-24-17 08:00AM  UMs Florida stock index bests S&P 500 at bizjournals.com
08:00AM  UMs Florida stock index bests S&P 500 American City Business Journals
Feb-23-17 04:59PM  HCI Group, Inc.: Strong price momentum but will it sustain? Capital Cube
12:53PM  HCI Group, Inc. :HCI-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017 Capital Cube
10:50AM  HCI Group, Inc. :HCI-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
Feb-22-17 05:06PM  HCI GROUP, INC. Files SEC form 10-K, Annual Report +10.44%
Feb-21-17 10:18PM  Edited Transcript of HCI earnings conference call or presentation 21-Feb-17 9:45pm GMT
05:22PM  HCI Group posts 4Q profit
04:44PM  HCI GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  HCI Group Reports Fourth Quarter and Full Year 2016 Results GlobeNewswire
07:07AM  Q4 2016 HCI Group Inc Earnings Release - After Market Close
Feb-20-17 04:05PM  Investor Network Invites You to the HCI Group Fourth Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday, February 21, 2017 Accesswire
09:08AM  XL Group Increases Dividend Payout, Okays Share Buyback
Feb-16-17 08:00AM  HCI Group to Participate at the 42nd Annual AIFA Conference on Tuesday, March 7, 2017 GlobeNewswire
Feb-01-17 08:00AM  HCI Group Real Estate Division Acquires 100% Ownership of Newly-Built Melbourne, Florida Shopping Center GlobeNewswire
Jan-31-17 08:00AM  HCI Group Sets Fourth Quarter and Full Year 2016 Earnings Call for Tuesday, February 21, 2017 at 4:45 p.m. ET GlobeNewswire
HCI Group, Inc. engages in the property and casualty insurance business in Florida. It provides property and casualty insurance to homeowners, condominium owners, and tenants; and reinsurance. The company also leases office properties and retail shopping centers; and owns and operates one full-service restaurant and two marinas. In addition, it offers designs and develops Web-based applications and products for mobile devices. The company was formerly known as Homeowners Choice, Inc. and changed its name to HCI Group, Inc. in May 2013. HCI Group, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Politis GregoryDirectorDec 19Buy29.102,00058,200196,000Dec 21 04:03 PM
Politis GregoryDirectorDec 18Buy29.972,00059,946194,000Dec 19 03:51 PM
Politis GregoryDirectorDec 15Buy29.282,00058,552192,000Dec 19 03:51 PM
Patel PareshChief Executive OfficerDec 08Buy30.301,00030,30035,000Dec 12 03:50 PM
Macchiarola James JDirectorNov 27Buy30.446,000182,6236,000Nov 29 03:55 PM
Harmsworth James MarkChief Financial OfficerSep 21Buy36.9350018,467500Sep 21 04:33 PM
Graham Andrew L.GC/Corporate SecretarySep 21Buy36.45652,3692,825Sep 21 04:31 PM
Patel PareshChief Executive OfficerSep 20Buy36.061,00036,062285,000Sep 21 04:29 PM
Patel PareshChief Executive OfficerJun 16Option Exercise2.5030,00075,000227,000Jun 20 03:48 PM
EDN Empresa Distribuidora y Comercializadora Norte Sociedad Anonima daily Stock Chart
EDN [NYSE]
Empresa Distribuidora y Comercializadora Norte Sociedad Anonima
Index- P/E39.38 EPS (ttm)1.49 Insider Own52.20% Shs Outstand22.02M Perf Week4.51%
Market Cap1.29B Forward P/E11.36 EPS next Y5.17 Insider Trans0.00% Shs Float21.50M Perf Month-1.16%
Income66.80M PEG0.61 EPS next Q- Inst Own19.40% Short Float0.33% Perf Quarter35.18%
Sales1.10B P/S1.18 EPS this Y-204.00% Inst Trans15.90% Short Ratio1.01 Perf Half Y69.72%
Book/sh1.19 P/B49.30 EPS next Y326.16% ROA6.40% Target Price52.50 Perf Year74.09%
Cash/sh4.31 P/C13.61 EPS next 5Y64.70% ROE177.90% 52W Range28.88 - 63.29 Perf YTD18.05%
Dividend- P/FCF- EPS past 5Y-48.50% ROI2.70% 52W High-7.30% Beta1.71
Dividend %- Quick Ratio0.60 Sales past 5Y35.20% Gross Margin51.10% 52W Low103.15% ATR2.89
Employees4692 Current Ratio0.60 Sales Q/Q89.40% Oper. Margin14.50% RSI (14)56.94 Volatility3.51% 4.94%
OptionableNo Debt/Eq3.01 EPS Q/Q144.30% Profit Margin6.10% Rel Volume0.20 Prev Close58.27
ShortableYes LT Debt/Eq2.89 EarningsMar 01 BMO Payout0.00% Avg Volume69.95K Price58.67
Recom2.30 SMA201.08% SMA508.19% SMA20044.22% Volume13,932 Change0.69%
May-28-08Downgrade Citigroup Buy → Hold
May-12-08Downgrade JP Morgan Overweight → Neutral
Jun-15-07Initiated Bear Stearns Outperform $24
Nov-27-17 01:15PM  ETFs with exposure to Edenor SA : November 27, 2017 Capital Cube
Nov-15-17 11:46AM  ETFs with exposure to Edenor SA : November 15, 2017 Capital Cube
Sep-15-17 11:35PM  [$$] Argentina Makes Progress on Economic Reforms Barrons.com
May-24-17 10:21AM  Edenor SA :EDN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
Apr-28-17 04:32PM  Edenor Informs The Market Of The Filing Of Its Annual Report On Form 20-F For The Fiscal Year Ended December 31, 2016. PR Newswire
Apr-11-17 01:40PM  Edenor SA :EDN-US: Earnings Analysis: Q4, 2016 By the Numbers : April 11, 2017 Capital Cube
11:13AM  Edenor SA :EDN-US: Earnings Analysis: 2016 By the Numbers : April 11, 2017 Capital Cube
Feb-08-17 10:25AM  Top Ranked Momentum Stocks to Buy for February 8th Zacks
Feb-01-17 08:45AM  Empresa (EDN) Worth a Looks: Stock Adds 7.6% in Session Zacks
Dec-01-16 04:47PM  5 Utility Stocks You Can Do Without This December
Nov-21-16 11:06AM  Edenor SA :EDN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Capital Cube
11:06AM  Edenor SA :EDN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Aug-19-16 10:58AM  Edenor SA :EDN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 19, 2016 Capital Cube
10:58AM  Edenor SA :EDN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 19, 2016
Aug-18-16 05:21PM  Argentina: Tax Amnesty For $400B In Hidden Assets? at Barrons.com
Jul-27-16 01:04PM  EDENOR Financials
May-26-16 11:39AM  Edenor SA :EDN-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 +5.85%
May-11-16 12:43PM  Genneia S.A. -- Moody's recalibrates Argentina's national rating scale and repositions national scale ratings of infrastructure issuers. Moody's
12:43PM  Genneia S.A. -- Moody's recalibrates Argentina's national rating scale and repositions national scale ratings of infrastructure issuers. at Moody's
May-04-16 01:04PM  EDENOR Financials EDGAR Online Financials
Apr-27-16 07:32PM  Edenor informs the market of the filing of its annual report on form 20-F for the fiscal year ended december 31, 2015 PR Newswire
Apr-21-16 03:20PM  Genneia S.A. -- Moody's upgrades Argentine Utilities and Infrastructure issuers Moody's
03:20PM  Genneia S.A. -- Moody's upgrades Argentine Utilities and Infrastructure issuers at Moody's
03:12PM  Aeropuertos Argentina 2000 S.A. -- Moody's upgrades Argentine Utilities and Infrastructure issuers at Moody's
03:12PM  Aeropuertos Argentina 2000 S.A. -- Moody's upgrades Argentine Utilities and Infrastructure issuers at Moody's
Mar-23-16 10:42AM  Edenor SA :EDN-US: Earnings Analysis: Q4, 2015 By the Numbers Capital Cube
Mar-22-16 02:22PM  Edenor SA :EDN-US: Earnings Analysis: 2015 By the Numbers
Feb-01-16 07:23PM  Empresa Distribuidora Norte S.A. -- Moody's upgrades Edenor ratings to Caa2/Ba2.ar; outlook positive Moody's
07:12PM  Empresa Distribuidora Norte S.A. -- Moody's upgrades Edenor ratings to Caa2; outlook positive at Moody's
Dec-21-15 01:10PM  Edenor SA Earnings Analysis: Q3, 2015 By the Numbers
Nov-27-15 08:27PM  More And More Hedge Funds Are Selling Silver Bay Realty Trust Corp (SBY) at Insider Monkey
Nov-26-15 03:49AM  Is Blueprint Medicines Corp (BPMC) Going to Burn These Hedge Funds? at Insider Monkey
Nov-16-15 09:00PM  Zombie Bonds No More as Argentina Vote Stokes Utilities Windfall at Bloomberg
Nov-04-15 05:45PM  Genneia S.A. -- Moody's changes outlook to stable for Argentine Infrastructure Issuers; places Edenor under review for upgrade at Moody's
05:38PM  Aeropuertos Argentina 2000 S.A. -- Moody's changes EDESA's outlook to stable, affirms TGS and AA2000 ratings and places Edenor under review for upgrade at Moody's
Aug-28-15 11:49AM  Edenor SA Earnings Q2, 2015
Aug-24-15 06:21PM  Edenor Informs The Market Of The Filing Of Its Annual Report On Form 20-F For The Fiscal Year Ended December 31, 2014 PR Newswire
03:56PM  Argentina To Sell State Stake In Stocks? at Barrons.com
Jul-10-15 11:35AM  Mid-Morning Market Update: Markets Surge; PriceSmart Posts Mixed Results
Mar-18-15 08:18AM  Fourth Q.14 - Earnings Release at noodls
Jan-09-15 01:45PM  EDENOR S.A. Informs to the Market that it has Filed its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2013 PR Newswire
Sep-05-14 06:01PM  Emerging Market Week in Review at Barrons.com
Sep-04-14 05:42PM  Argentina Stocks Drop On Bond Default Vote at Barrons.com
Aug-28-14 11:14AM  Empresa Distribuidora Y Comercializadora No Stock Downgraded (EDN) at TheStreet
Aug-26-14 02:56PM  Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints
01:10PM  DSW Jumps On Upbeat Results; Trina Solar Shares Drop
Jul-31-14 10:09AM  [video] Argentina disputing debt default at CNBC
09:15AM  [video] ISDA requested to make Argentina ruling at CNBC
07:03AM  [video] Argentine stocks tumble after default news at CNBC
Jul-09-14 01:03PM  Today's Top Performers In Utilities at TheStreet
Jul-01-14 05:46PM  4 Emerging Markets Stocks On Winning Streaks at Seeking Alpha
Jun-26-14 02:10PM  What Will Happen to These ADRs if Argentina Defaults? at Motley Fool
Jun-24-14 03:15PM  Utility Sector Rises; Elizabeth Arden Shares Slide Over 3.6% Benzinga
12:36PM  Micron Gains On Upbeat Earnings; Elizabeth Arden Shares Slide Benzinga
Jun-17-14 09:26AM  Stock Downgrades: Travelers Going Nowhere Fast at Minyanville
05:49AM  Argentina refuses to submit to 'extortion' on debt at Financial Times
04:44AM  Argentina Heads For Another Sovereign Default at Forbes
Mar-17-14 07:46AM  4 Stocks Under $10 Making Big Moves at TheStreet
Mar-11-14 04:57AM  SectorCast Rankings Take A Neutral Slant As Market Hits New Highs at Seeking Alpha
Feb-08-14 10:18AM  Edenor: Trading At A Bargain Price at Seeking Alpha
Jan-26-14 08:23AM  Avoid Argentina Stocks This Year at Seeking Alpha
Dec-13-13 09:34AM  4 Stocks Under $10 to Trade for Breakouts Optionetics
Nov-15-13 08:13AM  4 Stocks Under $10 to Trade for Breakouts Optionetics
Sep-06-13 03:24PM  Empresa Distribuidora Norte S.A. -- Moody's downgrades Edenor's to Caa3/Caa3.ar; Negative outlook Moody's
Apr-16-13 06:40PM  Dividend yielding stocks that stand apart as multiples swell at MarketWatch
Feb-26-13 10:34AM  Argentina's Errant Energy Policy at Motley Fool
Nov-26-12 04:13AM  Should You Invest In Argentina Stocks Now? at Seeking Alpha
Aug-24-12 04:41PM  Utilities Sector Wrap at Fox Business
Jul-25-12 05:40PM  Utilities Sector Wrap at Fox Business
Jul-05-12 05:39PM  Utilities Sector Wrap at Fox Business
Jun-04-12 05:12PM  Utilities Sector Wrap at Fox Business
May-31-12 04:56PM  Utilities Sector Wrap at Fox Business
May-23-12 12:50PM  Empresa Distribuidora y Comercializadora Norte, School Specialty: Biggest Price Gainers (EDN, SCHS) at The Wall Street Journal
May-21-12 04:56PM  Utilities Sector Wrap at Fox Business
May-09-12 04:56PM  Utilities Sector Wrap at Fox Business
May-08-12 04:56PM  Utilities Sector Wrap at Fox Business
Apr-27-12 11:20AM  Are Argentinean Companies at Risk of Being Expropriated? at Motley Fool
Apr-26-12 04:56PM  Utilities Sector Wrap at Fox Business
04:04PM  Edenor Informs the Market of the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2011 PR Newswire
Apr-23-12 09:06AM  Argentina's Wasted Chances at Seeking Alpha
Apr-18-12 10:26AM  Polaris, Calpine hit new highs; Seagate active at MarketWatch
Apr-17-12 07:34PM  YPF slumps to three-year low on takeover move at MarketWatch
04:50PM  Empresa Distribuidora y Comercializadora Norte, China Finance Online: Biggest Price Decliners (EDN, JRJC) at The Wall Street Journal
12:06PM  Tuesday Sector Laggards: Electric Utilities, Cigarettes & Tobacco Stocks at Forbes
11:30AM  [video] Tuesday Sector Laggards: Electric Utilities, Cigarettes & Tobacco Stocks at Forbes
Dec-20-11 03:30AM  2 Utilities To Add Utility To Your Portfolio at Seeking Alpha
Nov-03-11 03:39AM  10 Foreign Utility Stocks To Consider at Seeking Alpha
Nov-01-11 10:58AM  The AES Corp Third Quarter Earnings Sneak Peek Wall St. Cheat Sheet
Oct-20-11 12:13PM  El Paso Corporation and Williams Companies Lead the Way Higher in the Utilities Sector Wall St. Cheat Sheet
Oct-11-11 02:44PM  The Fastest-Growing Electric Utility Stocks at Motley Fool
Aug-05-11 08:30AM  The AES Earnings Cheat Sheet: Revenue, Net Income Climbs Wall St. Cheat Sheet
Jul-28-11 07:07PM  The AES Corp Second Quarter Earnings Sneak Peek Wall St. Cheat Sheet
Jul-22-11 12:00AM  Italian Stocks - Factors to watch on July 22 at Reuters
Jul-15-11 03:25PM  Vectren Corp Passes Through 5% Yield Mark at Forbes
Jun-28-11 02:10PM  UPDATE 1-Lactalis wins Parmalat control battle at Reuters
09:42AM  Lactalis poised to win Parmalat control battle at Reuters
Jun-24-11 03:36PM  Utes And Auto Parts Thrive On Friday at Forbes
12:00AM  Italian Stocks - Factors to watch on June 24 at Reuters
Jun-22-11 12:00AM  Italian Stocks - Factors to watch on June 22 at Reuters
Jun-21-11 07:11AM  UPDATE 1-Italy seeking to keep Edison in Italian hands at Reuters
Empresa Distribuidora y Comercializadora Norte Sociedad Anonima, a public service company, engages in the distribution and sale of electricity in Argentina. The company was formerly known as Empresa Distribuidora Norte Sociedad Anonima and changed its name to Empresa Distribuidora y Comercializadora Norte Sociedad Anonima in June 1996. The company was founded in 1992 and is based in Buenos Aires, Argentina. Empresa Distribuidora y Comercializadora Norte Sociedad Anonima is a subsidiary of Electricidad Argentina S.A.
KLIC Kulicke and Soffa Industries, Inc. daily Stock Chart
KLIC [NASD]
Kulicke and Soffa Industries, Inc.
Index- P/E64.29 EPS (ttm)0.35 Insider Own1.30% Shs Outstand71.48M Perf Week3.93%
Market Cap1.63B Forward P/E11.00 EPS next Y2.07 Insider Trans-0.16% Shs Float69.54M Perf Month-10.78%
Income27.10M PEG5.36 EPS next Q0.40 Inst Own88.20% Short Float0.58% Perf Quarter-15.07%
Sales873.10M P/S1.86 EPS this Y133.70% Inst Trans-0.42% Short Ratio0.67 Perf Half Y20.61%
Book/sh12.05 P/B1.89 EPS next Y24.18% ROA2.40% Target Price34.07 Perf Year9.06%
Cash/sh9.09 P/C2.50 EPS next 5Y12.00% ROE3.10% 52W Range18.22 - 28.71 Perf YTD-6.47%
Dividend- P/FCF12.66 EPS past 5Y-6.10% ROI11.50% 52W High-20.72% Beta1.35
Dividend %- Quick Ratio5.10 Sales past 5Y0.50% Gross Margin46.50% 52W Low24.92% ATR0.93
Employees2778 Current Ratio5.70 Sales Q/Q42.80% Oper. Margin13.70% RSI (14)48.90 Volatility3.72% 4.74%
OptionableYes Debt/Eq0.02 EPS Q/Q-552.40% Profit Margin3.10% Rel Volume0.84 Prev Close22.79
ShortableYes LT Debt/Eq0.02 EarningsJan 31 BMO Payout0.00% Avg Volume596.46K Price22.76
Recom1.30 SMA200.60% SMA50-4.84% SMA2002.86% Volume503,728 Change-0.13%
Nov-18-16Downgrade Standpoint Research Buy → Hold
Jul-09-15Initiated Singular Research Buy $16.50
Sep-30-13Initiated Standpoint Research Buy $17
Jan-07-11Upgrade Oppenheimer Underperform → Outperform $5 → $11
Oct-12-10Downgrade Jefferies Buy → Hold $10.20 → $6
Sep-14-10Downgrade Oppenheimer Perform → Underperform $10 → $5
Jul-09-10Initiated DA Davidson Buy $14
Apr-14-10Reiterated Oppenheimer Perform $8 → $10
Aug-19-09Initiated Jefferies & Co Buy $6.20
Dec-03-08Reiterated AmTech Research Buy $8 → $4.25
Aug-07-08Reiterated AmTech Research Buy $10 → $8
Jul-10-08Initiated Banc of America Sec Neutral
Jun-16-08Upgrade AmTech Research Neutral → Buy $10
Apr-08-08Initiated Oppenheimer Outperform $5
Jan-08-08Downgrade AmTech Research Buy → Neutral
Nov-16-07Reiterated AmTech Research Buy $12.75 → $9.60
Sep-05-07Initiated Banc of America Sec Neutral $9.75
Feb-20-07Downgrade Matrix Research Strong Buy → Strong Sell
Feb-05-07Upgrade Am Tech/JSA Research Neutral → Buy
Feb-22-18 02:00PM  Top Ranked Growth Stocks to Buy for February 22nd InvestorPlace
09:54AM  Top Ranked Growth Stocks to Buy for February 22nd Zacks
09:16AM  Zacks.com featured highlights include: Kulicke and Soffa, ArcelorMittal, Citizens Financial, Hitachi and Volkswagen Zacks
09:08AM  Zacks.com featured highlights include: Covenant Transportation, Kulicke and Soffa, TrueBlue, Haverty Furniture and Graphic Packaging Zacks
Feb-12-18 08:13AM  Zacks.com highlights: Kulicke and Soffa Industries, SK Telecom, Post Holdings and Delta Apparel Zacks
Feb-09-18 09:05AM  Kulicke & Soffa Receives New Order for High-Performance Die Attach Equipment APAMA DA Business Wire
09:04AM  5 Tech Growth Stocks to Click With Investors Despite Selloff Zacks
06:49AM  Buy 4 Stocks With Rising Cash Flows This Earnings Season Zacks
Feb-08-18 07:40AM  The Zacks Analyst Blog Highlights: Huntsman, Tutor Perini, OceanFirst, GeoPark and Kulicke and Soffa Zacks
Feb-07-18 08:23AM  Zacks.com featured highlights include: Citizens Financial, Hitachi, Volkswagen, Kulicke and Soffa and Greenbrier Zacks
Jan-31-18 06:33PM  Kulicke and Soffa reports 1Q loss Associated Press
05:00PM  Kulicke & Soffa Reports First Quarter 2018 Results Business Wire
Jan-29-18 09:05AM  Kulicke & Soffa to Participate at SEMICON Korea 2018 Business Wire
Jan-19-18 09:33AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Kulicke and Soffa Industries, Inc. -- KLIC Business Wire
07:25AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Kulicke & Soffa Industries, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jan-18-18 09:05AM  Kulicke & Soffa Schedules First Quarter 2018 Conference Call for 6PM EST, Jan 31st, 2018 Business Wire
Jan-15-18 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Dec-29-17 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Dec-28-17 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Dec-25-17 12:04PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : December 25, 2017 Capital Cube
Dec-12-17 01:28PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : December 12, 2017 Capital Cube
Dec-08-17 09:19AM  Kulicke & Soffa Industries, Inc. :KLIC-US: Earnings Analysis: Q4, 2017 By the Numbers : December 8, 2017 Capital Cube
Dec-04-17 09:05AM  Kulicke & Soffa Netherlands Wins Best Customer Award (DISCA) Business Wire
Dec-01-17 02:03PM  10 A-Rated Tech Stocks to Grow Your Returns InvestorPlace
Nov-29-17 08:35AM  Kulicke and Soffa (KLIC): Strong Industry, Solid Earnings Estimate Revisions Zacks
Nov-27-17 06:00AM  Kulicke & Soffa Industries, Inc. Announces Appointment of New CFO Business Wire
Nov-24-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Nov-21-17 11:58AM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : November 21, 2017 Capital Cube
Nov-20-17 10:25AM  Kulicke & Soffa Industries, Inc. :KLIC-US: Earnings Analysis: 2017 By the Numbers : November 20, 2017 Capital Cube
09:35AM  Should Value Investors Pick Kulicke and Soffa (KLIC) Stock Now? Zacks
Nov-17-17 11:00AM  What Do Cato, Hibbett Sports and Kulicke & Soffa Have in Common? Big Jumps TheStreet.com
Nov-16-17 02:36AM  Edited Transcript of KLIC earnings conference call or presentation 14-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
Nov-15-17 11:11AM  Kulicke & Soffa Industries, Inc.: Strong price momentum but will it sustain? Capital Cube -9.64%
08:58AM  Kulicke and Soffa (KLIC) Jumps: Stock Rises 20.4% Zacks
Nov-14-17 04:30PM  Why Buffalo Wild Wings, Mattel, and Kulicke and Soffa Industries Jumped Today Motley Fool +20.39%
04:09PM  This Top Chip-Gear Maker Soars 20% On Strong Earnings Investor's Business Daily
01:52PM  Why Kulicke and Soffa Industries Shares Jumped Today Motley Fool
08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
07:08AM  Kulicke and Soffa posts 4Q profit Associated Press
06:55AM  Kulicke & Soffa Reports Fourth Quarter & Fiscal Year 2017 Results Business Wire
05:59AM  Kulicke and Soffa Industries Inc (KLIC): Poised For Long-Term Success? Simply Wall St.
Nov-13-17 04:15PM  Investor Network Invites You to the Kulicke & Soffa Fourth Quarter and Full Year 2017 Earnings Webcast and Conference Call Live on Tuesday, November 14, 2017 ACCESSWIRE
09:05AM  Kulicke & Soffa to Participate at Productronica 2017 Business Wire
Nov-08-17 08:38AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Nov-07-17 08:13AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Nov-06-17 01:26PM  Stocks Rise; Chips In Focus, But This Other Sector Is Making Breakouts Investor's Business Daily
Nov-01-17 09:05AM  Kulicke & Soffa Schedules Fourth Quarter & Full Year 2017 Conference Call for 8AM EST, November 14th, 2017 Business Wire
Oct-09-17 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Oct-05-17 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Sep-29-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Sep-25-17 08:04AM  Kulicke & Soffa Industries, Inc. breached its 50 day moving average in a Bullish Manner : KLIC-US : September 25, 2017 Capital Cube
Sep-15-17 08:05AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
03:00AM  Kulicke & Soffa Industries Getting Closer To Key Technical Measure Investor's Business Daily
Sep-13-17 03:00AM  Stocks With Rising Relative Strength: Kulicke & Soffa Industries Investor's Business Daily
Sep-11-17 09:05AM  Kulicke & Soffa to Participate at SEMICON Taiwan 2017 Business Wire
Sep-07-17 01:20PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : September 7, 2017 Capital Cube
Sep-06-17 10:11AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
09:05AM  Kulicke & Soffa and Kinik Sign Collaboration Agreement to Provide Comprehensive Dicing Blades Solutions Business Wire
Sep-04-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Sep-01-17 02:53PM  Kulicke & Soffa Industries, Inc. :KLIC-US: Earnings Analysis: Q3, 2017 By the Numbers : September 1, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-31-17 08:11AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-30-17 08:05AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-28-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-24-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-17-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-16-17 09:23PM  Kulicke & Soffa Industries, Inc. Value Analysis (NASDAQ:KLIC) : August 17, 2017 Capital Cube
08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-15-17 09:05AM  Kulicke & Soffa Completes Existing $100M Repurchase Program Business Wire
08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-12-17 09:25AM  Edited Transcript of KLIC earnings conference call or presentation 2-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-11-17 08:07AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-09-17 08:06AM  See what the IHS Markit Score report has to say about Kulicke and Soffa Industries Inc. Markit
Aug-03-17 09:07AM  Kulicke & Soffa Industries, Inc. breached its 50 day moving average in a Bearish Manner : KLIC-US : August 3, 2017 Capital Cube
Aug-02-17 09:58PM  Kulicke and Soffa posts 3Q profit Associated Press -12.02%
01:18PM  Kulicke & Soffa Misses Estimates, Chip Gear Makers Fall Investor's Business Daily
06:55AM  Kulicke & Soffa Reports Third Quarter 2017 Results Business Wire
06:00AM  Investor Network: Kulicke & Soffa Industries, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 04:10PM  Investor Network Invites You to the Kulicke & Soffa Third Fiscal Quarter 2017 Earnings Webcast and Conference Call Live on Wednesday, August 2, 2017 ACCESSWIRE
Jul-24-17 04:53PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : July 24, 2017 Capital Cube
Jul-18-17 09:05AM  Kulicke & Soffa Schedules Third Quarter 2017 Conference Call for 8AM EDT, August 2nd, 2017 Business Wire
Jul-14-17 03:13PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : July 14, 2017 Capital Cube
Jul-13-17 12:13PM  Recapping The Semicon West Trade Show: Winners And Losers Benzinga
Jul-12-17 08:18AM  Kulicke & Soffa Industries, Inc. breached its 50 day moving average in a Bullish Manner : KLIC-US : July 12, 2017 Capital Cube
Jul-10-17 09:05AM  Kulicke & Soffa to Participate at SEMICON West 2017 Business Wire
Jul-06-17 09:00AM  Kulicke & Soffa Further Expands Advanced Packaging Presence through Strategic Lithography Acquisition Business Wire
Jul-05-17 09:30AM  Zacks.com featured highlights: ON Semiconductor, Kulicke and Soffa Industries, CEMEX, Office Depot and Citizens Financial Group Zacks
Jul-03-17 08:58AM  5 Low Price-to-Book Stocks for Big Returns Zacks
Jun-29-17 12:08PM  Can Kulicke & Soffa 'KLIC' With Investors? TheStreet.com
Jun-28-17 04:00PM  Kulicke & Soffa Provides Updates to Its Third Quarter Business Outlook; Provides Full Fiscal Year 2017 Revenue Guidance Business Wire
Jun-22-17 09:30AM  Zacks.com featured highlights: Rocky Brands, Autobytel, Kulicke and Soffa Industries, Hitachi and SK Telecom Zacks
Jun-15-17 02:20PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : June 15, 2017 Capital Cube
Jun-13-17 08:44AM  Kulicke & Soffa Industries, Inc. breached its 50 day moving average in a Bearish Manner : KLIC-US : June 13, 2017 Capital Cube
Jun-02-17 08:51AM  Surging Earnings Estimates Signal Good News for Kulicke and Soffa (KLIC) Zacks
May-31-17 12:37PM  ETFs with exposure to Kulicke & Soffa Industries, Inc. : May 31, 2017 Capital Cube
May-30-17 08:58AM  Why Kulicke and Soffa Industries (KLIC) Might Be a Diamond in the Rough Zacks
May-29-17 09:07AM  Kulicke & Soffa Industries, Inc. :KLIC-US: Earnings Analysis: Q2, 2017 By the Numbers : May 29, 2017 Capital Cube
May-13-17 08:12AM  3 Winning Stocks You Never Saw Coming Motley Fool
Kulicke and Soffa Industries, Inc. designs, manufactures, and sells capital equipment and expendable tools to assemble semiconductor devices. It operates in two segments: Capital Equipment, and Aftermarket Products and Services (APS). The Capital Equipment segment manufactures and sells a line of ball bonders, wafer level bonders, wedge bonders, advanced packaging, and electronic assembly solutions. The APS segment manufactures and sells various tools for a range of semiconductor packaging applications, which include capillaries, which are expendable tools used in ball bonders; dicing blades that are expendable tools for semiconductor manufacturers to cut silicon wafers into individual semiconductor die or to cut packaged semiconductor units into individual units; and bonding wedges, which are expendable tools used in heavy wire wedge bonders. This segment also provides spare parts, equipment repair, maintenance and servicing, training services, and equipment upgrading services. The company serves semiconductor device manufacturers, integrated device manufacturers, outsourced semiconductor assembly and test providers, other electronics manufacturers, industrial manufacturers, and automotive electronics suppliers primarily in the United States and the Asia/Pacific region. Kulicke and Soffa Industries, Inc. was founded in 1951 and is headquartered in Singapore.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BACHMAN BRIAN RDirectorJan 02Sale24.474009,78819,171Jan 04 09:02 AM
BACHMAN BRIAN RDirectorNov 16Sale26.2550013,12518,243Nov 20 09:34 AM
Wong Nelson MunPunVice PresidentOct 08Option Exercise0.004,622088,238Oct 10 10:03 AM
Wong Lester ASenior Vice PresidentOct 08Option Exercise0.006,933079,349Oct 10 10:01 AM
Sood DeepakVice PresidentOct 08Option Exercise0.006,9330107,235Oct 10 09:57 AM
Lee IreneSenior Vice PresidentOct 08Option Exercise0.006,933071,846Oct 10 09:53 AM
Chou JonathanExecutive Vice President, CFOOct 08Option Exercise0.0019,6430193,016Oct 10 09:50 AM
Chong Chan PinSenior Vice PresidentOct 08Option Exercise0.001,309035,752Oct 10 09:46 AM
PIERCE GARRETT EDirectorOct 05Sale22.0359213,041120,499Oct 10 08:42 AM
CHEN FUSEN ERNIEPresident and CEOSep 30Option Exercise0.0014,5390152,832Oct 03 01:31 PM
PIERCE GARRETT EDirectorJul 07Sale19.5669013,496119,613Jul 11 08:45 AM
PIERCE GARRETT EDirectorApr 10Sale19.8465212,936118,577Apr 12 09:03 AM
PCRX Pacira Pharmaceuticals, Inc. daily Stock Chart
PCRX [NASD]
Pacira Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own0.40% Shs Outstand48.58M Perf Week-14.90%
Market Cap1.48B Forward P/E60.74 EPS next Y0.50 Insider Trans-33.75% Shs Float40.37M Perf Month-22.36%
Income-51.20M PEG- EPS next Q0.10 Inst Own- Short Float8.03% Perf Quarter-24.10%
Sales280.50M P/S5.29 EPS this Y-114.50% Inst Trans-3.33% Short Ratio3.63 Perf Half Y-14.55%
Book/sh6.54 P/B4.67 EPS next Y744.40% ROA-9.30% Target Price47.83 Perf Year-30.80%
Cash/sh6.05 P/C5.05 EPS next 5Y35.15% ROE-20.20% 52W Range29.35 - 58.95 Perf YTD-33.08%
Dividend- P/FCF- EPS past 5Y16.50% ROI-9.80% 52W High-48.18% Beta1.82
Dividend %- Quick Ratio6.20 Sales past 5Y77.50% Gross Margin67.80% 52W Low4.09% ATR2.30
Employees503 Current Ratio7.00 Sales Q/Q-1.60% Oper. Margin-14.10% RSI (14)30.58 Volatility6.27% 6.08%
OptionableYes Debt/Eq1.03 EPS Q/Q68.40% Profit Margin-18.20% Rel Volume0.95 Prev Close30.15
ShortableYes LT Debt/Eq1.03 EarningsFeb 28 BMO Payout- Avg Volume893.05K Price30.55
Recom2.40 SMA20-16.43% SMA50-24.64% SMA200-25.54% Volume844,919 Change1.33%
Feb-16-18Downgrade Needham Buy → Hold
Jan-19-18Initiated Seaport Global Securities Buy $50
Jan-04-18Reiterated Canaccord Genuity Buy $42 → $46
Jan-03-18Initiated Leerink Partners Mkt Perform $46
Dec-18-17Initiated JP Morgan Neutral $47
Nov-29-17Downgrade Mizuho Buy → Neutral $53 → $44
Nov-09-17Resumed H.C. Wainwright Buy $52
Oct-26-17Downgrade Janney Neutral → Sell
Oct-19-17Reiterated Needham Buy $55 → $52
Sep-28-17Initiated Goldman Neutral $41
Sep-07-17Initiated Oppenheimer Perform
Aug-22-17Initiated Needham Buy $55
Aug-21-17Upgrade Janney Sell → Neutral
May-05-17Reiterated Mizuho Buy $57 → $54
Apr-13-17Initiated RBC Capital Mkts Outperform $58
Mar-23-17Reiterated Mizuho Buy $59 → $54
Mar-21-17Reiterated Barclays Overweight $54 → $59
Mar-02-17Reiterated H.C. Wainwright Buy $48 → $59
Feb-22-17Initiated Canaccord Genuity Buy $55
Jan-03-17Initiated H.C. Wainwright Buy $43
Feb-22-18 04:00PM  Pacira Pharmaceuticals Announces Timing for 2017 Financial Results Webcast and Conference Call GlobeNewswire
Feb-20-18 10:41AM  Heres Whats Moving Apricus Biosciences And Pacira Pharmaceuticals Market Exclusive
Feb-16-18 04:15PM  This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% Investor's Business Daily -16.48%
07:30AM  Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference GlobeNewswire
Feb-15-18 05:26PM  FDA Panel Votes 6-4 Against Recommending This Biotech's Pain Blocker Investor's Business Daily
03:34PM  Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia GlobeNewswire
08:15AM  Consolidated Research: 2018 Summary Expectations for Pacira Pharmaceuticals, Wabash National, Spirit Airlines, Praxair, Altice, and Gap Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-14-18 04:39PM  What You Must Know About Pacira Pharmaceuticals Incs (NASDAQ:PCRX) Financial Strength Simply Wall St.
01:28PM  Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia GlobeNewswire
Feb-12-18 01:29PM  FDA Posts Briefing Documents for Advisory Meeting Reviewing sNDA for EXPAREL® as a Nerve Block for Regional Analgesia GlobeNewswire
Feb-09-18 08:50AM  Implied Volatility Surging for Pacira (PCRX) Stock Options Zacks
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Jan-08-18 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
07:30AM  WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures GlobeNewswire
Jan-05-18 08:02AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Jan-04-18 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit -7.44%
07:30AM  Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million GlobeNewswire
Jan-03-18 07:30AM  Pacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-18 08:05AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Dec-28-17 08:02AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Dec-27-17 03:00AM  IBD Rating Upgrades: Pacira Pharmaceuticals Shows Improved Relative Price Strength Investor's Business Daily
Dec-26-17 11:58AM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:30AM  Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-14-17 07:30AM  Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients GlobeNewswire
Dec-13-17 03:00AM  Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating Investor's Business Daily
Dec-11-17 02:45AM  Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue? Zacks
Dec-08-17 07:30AM  Pacira Pharmaceuticals to Present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
03:00AM  Pacira Pharmaceuticals Sees RS Rating Climb To 75 Investor's Business Daily
Dec-07-17 07:38AM  Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer MarketWatch
07:30AM  Pacira Announces Promotions of Scott Braunstein, MD, to Chief Operating Officer and Richard Scranton, MD, to Chief Scientific Officer GlobeNewswire
Dec-01-17 08:10AM  Recent Analysis Shows Praxair, Rockwell Automation, Gap, Pacira Pharmaceuticals, Wabash National, and Spirit Airlines Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-29-17 07:00AM  Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to Educate Physicians and Patients about Responsible Opioid Use PR Newswire
03:00AM  Stocks Flashing Renewed Technical Strength: Pacira Pharmaceuticals Investor's Business Daily
Nov-27-17 08:05AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Nov-22-17 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Nov-20-17 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Nov-17-17 08:05AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Nov-16-17 07:13AM  Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo Zacks
Nov-15-17 10:19AM  Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee Zacks
Nov-14-17 04:21PM  This Biotech Is Feeling The Pain After FDA Sets Panel On Anesthetic Investor's Business Daily -6.61%
07:30AM  Pacira Announces FDA Advisory Committee Meeting to Review sNDA for EXPAREL® as a Nerve Block for Regional Analgesia GlobeNewswire
Nov-12-17 12:41AM  Edited Transcript of PCRX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 05:00PM  Pacira Pharmaceuticals to Present at Two November Healthcare Conferences GlobeNewswire
Nov-08-17 04:13PM  The Bottom Line on Why Pacira Pharmaceuticals Inc. Rocketed Higher by as Much as 24% Motley Fool +16.98%
07:39AM  Pacira reports 3Q loss Associated Press
07:30AM  Pacira Pharmaceuticals, Inc. Reports Third Quarter 2017 Financial Results Marketwired
Nov-07-17 11:18AM  Pacira Pharmaceuticals, Inc. Value Analysis (NASDAQ:PCRX) : November 7, 2017 Capital Cube
Nov-06-17 12:17PM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : November 6, 2017 Capital Cube
07:17AM  Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : November 6, 2017 Capital Cube
Nov-01-17 08:02AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Oct-31-17 07:30AM  Pacira Pharmaceuticals Announces Timing for Third Quarter 2017 Financial Results Webcast and Conference Call GlobeNewswire
Oct-27-17 08:02AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Oct-25-17 08:00AM  Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement GlobeNewswire
Oct-24-17 09:41AM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 24, 2017 Capital Cube
Oct-20-17 07:20AM  Featured Company News - Pacira Announces FDA Acceptance of sNDA for EXPAREL ACCESSWIRE
Oct-19-17 08:04AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Oct-18-17 07:30AM  Pacira Pharmaceuticals Announces FDA Acceptance of sNDA for EXPAREL as a Nerve Block to Produce Regional Analgesia GlobeNewswire
Oct-16-17 09:42AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Oct-13-17 11:08AM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 13, 2017 Capital Cube
Oct-06-17 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Oct-02-17 11:01AM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-29-17 09:05AM  Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
08:07AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-28-17 08:17AM  Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : September 28, 2017 Capital Cube
Sep-27-17 07:30AM  Pacira Pharmaceuticals CEO to Testify at White House Opioid Crisis Commission Meeting GlobeNewswire
Sep-26-17 08:00AM  New Research: Overprescribing of Postsurgical Opioids Poses a Serious Threat to Patients and their Communities; Women Undergoing Surgery are at Greatest Risk GlobeNewswire
Sep-25-17 08:07AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-20-17 07:30AM  Pacira Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-19-17 08:02AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-13-17 07:30AM  Pacira Pharmaceuticals, Aetna, and the American Association of Oral and Maxillofacial Surgeons Join Together in a Program to Reduce Opioid Exposure for Patients Undergoing Wisdom Tooth Extraction GlobeNewswire
Sep-12-17 08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-11-17 10:08AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-07-17 08:01AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Sep-06-17 07:30AM  Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations at the Upcoming New York School of Regional Anesthesia Annual Fall Symposium GlobeNewswire
Sep-05-17 07:30AM  Pacira Pharmaceuticals to Present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 07:30AM  Pacira Pharmaceuticals to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-24-17 06:21PM  Steven Cohen Plunges Into Opioid Replacement Maker Pacira GuruFocus.com
Aug-14-17 09:20AM  Pacira Pharmaceuticals Focuses on Exparel's Label Expansion Zacks
08:03AM  See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc. Markit
Aug-13-17 03:36AM  Edited Transcript of PCRX earnings conference call or presentation 2-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 06:31PM  [$$] Maverick Therapeutics Taps Former Pacira Executive as CEO The Wall Street Journal
Aug-09-17 07:30AM  Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference GlobeNewswire
Aug-07-17 06:31PM  Pacira Pharmaceuticals, Inc. Value Analysis (NASDAQ:PCRX) : August 7, 2017 Capital Cube
Aug-03-17 08:18AM  Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss Zacks
Aug-02-17 10:51PM  Pacira reports 2Q loss Associated Press
07:30AM  Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results GlobeNewswire
06:30AM  Investor Network: Pacira Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-27-17 02:26PM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : July 27, 2017 Capital Cube
Jul-26-17 02:34PM  Pacira Pharmaceuticals Inc (PCRX) and EXACT Sciences Corporation (EXAS) Are Shaking Up the Market SmarterAnalyst
09:35AM  Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PCRX-US : July 26, 2017 Capital Cube
07:30AM  Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty GlobeNewswire
Jul-25-17 05:00PM  Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call GlobeNewswire -12.42%
12:39PM  Why Pacira Pharmaceuticals Shares Are Crashing 15% Today Motley Fool
07:30AM  Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block GlobeNewswire
Jul-17-17 01:50PM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : July 17, 2017 Capital Cube
Jul-06-17 02:06PM  ETFs with exposure to Pacira Pharmaceuticals, Inc. : July 6, 2017 Capital Cube
Jun-30-17 08:04AM  4 Small-Cap Stocks Set to Grow EPS by at Least 400% Through 2020 Motley Fool
Jun-22-17 08:13AM  Pacira Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PCRX-US : June 22, 2017 Capital Cube
Jun-15-17 07:30AM  Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors GlobeNewswire
Jun-14-17 07:30AM  Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. Its development pipeline comprises DepoTranexamic Acid, a long-acting local antifibrinolytic agent, which is in Phase II clinical development for the treatment or prevention of excessive blood loss during surgery by preventing the breakdown of a clot; and DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. is headquartered in Parsippany, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STACK DAVID MCEO and ChairmanJan 10Option Exercise1.6128,88546,505129,331Jan 12 06:15 PM
STACK DAVID MCEO and ChairmanJan 10Sale40.1928,8851,160,975100,446Jan 12 06:15 PM
Riker Lauren BullaroVice President, FinanceDec 15Sale43.7034014,85810,442Dec 18 07:52 PM
Jones James BSVP & Chief Medical OfficerNov 20Sale41.1185034,94216,823Nov 20 06:43 PM
Williams Kristen MarieCAO and General CounselNov 17Option Exercise25.377,857199,33229,169Nov 20 06:44 PM
Williams Kristen MarieCAO and General CounselNov 17Sale40.007,857314,28021,312Nov 20 06:44 PM
Williams Kristen MarieCAO and General CounselNov 16Option Exercise25.372,14354,36823,455Nov 20 06:44 PM
Williams Kristen MarieCAO and General CounselNov 16Sale40.012,14385,74121,312Nov 20 06:44 PM
STACK DAVID MCEO and ChairmanNov 15Option Exercise1.6128,88546,505159,164Nov 17 05:15 PM
STACK DAVID MCEO and ChairmanNov 15Sale38.3458,8852,257,708100,279Nov 17 05:15 PM
Kronenfeld Mark A.DirectorNov 10Buy41.601,00041,6036,795Nov 13 08:03 PM
HASTINGS PAUL JDirectorAug 22Sale36.151,04437,7413,518Aug 24 08:30 PM
STACK DAVID MCEO and ChairmanAug 15Option Exercise1.6128,88546,505159,164Aug 17 06:55 PM
Williams Kristen MarieCAO and General CounselAug 15Sale36.753,461127,19221,312Aug 17 06:56 PM
STACK DAVID MCEO and ChairmanAug 15Sale36.3728,8851,050,547130,279Aug 17 06:55 PM
Froimson MarkDirectorAug 08Buy37.131003,713100Aug 16 08:43 PM
STACK DAVID MCEO and ChairmanJul 24Option Exercise1.6115,00024,150130,279Jul 26 05:28 PM
STACK DAVID MCEO and ChairmanJun 23Option Exercise1.6115,00024,150115,059Jun 27 08:22 PM
Riker Lauren BullaroVice President, FinanceJun 07Sale44.371,11949,6507,063Jun 09 07:08 PM
Williams Kristen MarieCAO and General CounselJun 05Sale43.321,87781,31413,773Jun 07 07:03 PM
STACK DAVID MCEO and ChairmanJun 05Sale43.324,311186,75759,559Jun 07 07:02 PM
Scibetta James SPresidentJun 05Sale43.321,96685,16925,118Jun 07 07:00 PM
Jones James BSVP & Chief Medical OfficerJun 05Sale43.3276733,2279,813Jun 07 06:58 PM
Riker Lauren BullaroVice President, FinanceJun 05Sale43.3260126,0368,182Jun 07 06:59 PM
Braunstein ScottSVP, Strategy & Corp. Dev.Jun 05Sale43.3276833,2719,982Jun 07 06:57 PM
Scibetta James SPresidentMay 15Option Exercise5.4920,000109,80047,084May 17 06:44 PM
Williams Kristen MarieCAO and General CounselMay 15Option Exercise10.5021,041220,85636,691May 17 06:45 PM
Scibetta James SPresidentMay 15Sale51.2020,0001,024,00027,084May 17 06:44 PM
Williams Kristen MarieCAO and General CounselMay 15Sale50.8621,0411,070,14515,650May 17 06:45 PM